Erectile dysfunction is a marker for cardiovascular complications and psychological functioning in men with hypertension

Burchardt, Martin; Burchardt, Tatjana; ANASTASIADIS, A. G.; Kiss, AJ; Shabsigh, Ahmad; Taille, Alexandre de la; Pawar, RV; Baer, Leslie; Shabsigh, Ridwan

doi:10.1038/sj.ijir.3900725

Cited by 87 publications

(53 citation statements)

References 32 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another study self-reporting of ED in hypertensive patients is higher (71%) but the overall response to the questionnaire is low (22%). 23 It is probable that more patients who had not suffered this complication did not respond. In the MMAS, an association between complete ED and untreated hypertension or cardiac disease was not present.…”

Section: Disease States and Their Treatmentmentioning

confidence: 99%

Prevalence of erectile dysfunction and its correlates in Egypt: a community-based study

Seyam¹,

Al-Bakry²,

Ghobish³

et al. 2003

Int J Impot Res

View full text Add to dashboard Cite

We evaluated the prevalence of erectile dysfunction (ED) in a cross-sectional community-based random sample of Egyptian men. ED was correlated with the socioeconomic status, risk factors and quality of life. Married men in Ismailia province were interviewed at home. Data were processed for 805 men with mean age of 43.58 y (s.d. 11.03). There is a fair correlation between ED and increasing age (Po0.001). Males with complete ED comprised 13.2% of the sample, 26% of men in their 50s, 49% of men in their 60s and 52% of those 70 y or older. The state of better erection correlated fairly with sexual desire and sexual satisfaction (Po0.01). ED was associated with living in rural areas and lower socioeconomic level (Po0.01), with smoking, diabetes, heart disease, hypertension, liver disease, arthritis, peptic ulcer and renal disease (Po0.05). ED was negatively associated with good quality of life (Po0.001). These results indicate that ED is a common problem among married Egyptian men.

show abstract

Section: Disease States and Their Treatmentmentioning

confidence: 99%

Prevalence of erectile dysfunction and its correlates in Egypt: a community-based study

Seyam¹,

Al-Bakry²,

Ghobish³

et al. 2003

Int J Impot Res

View full text Add to dashboard Cite

show abstract

“…13 Studies have shown that patients seeking treatment for ED had undiagnosed hypertension, 8,14 and ischemic heart disease. 8 ED has been noticed among those with myocardial infarction, hypertension, 7,12,15,16 and other cardiac diseases. 5,8,12 ED has been regarded as a marker for disease progression for CVD.…”

Section: Introductionmentioning

confidence: 99%

Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study

et al. 2004

View full text Add to dashboard Cite

The association between erectile dysfunction (ED) and acute myocardial infarction (AMI) among men was examined in the Integrated Healthcare Information Services National Managed Care Benchmark Database (IHCIS). The IHCIS is a fully de-identified, HIPAA-compliant database and includes complete medical history for more than 17 million managed care lives; data from more than 30 US health plans, covering seven census regions; and patient demographics, including morbidity, age and gender. A total of 12 825 ED patients and an equal number of male patients without ED were included in the retrospective cohort study. Logistic regression analyses were performed to assess the adjusted risk of AMI that accounted for age at ED diagnosis, smoking, obesity and medications including ACE inhibitors, beta blockers and statins. The cohort of men with ED were observed to have a two-fold increase in the risk for AMI (OR ¼ 1.99, 95% CI ¼ 1.17, 3.38) after adjusting for age at ED diagnosis, smoking, obesity, and use of ACE inhibitors, beta blockers and statins. Some evidence of a possible trend toward increased risk was detected by age group. After controlling for the aforementioned covariates and compared to men 30-39 y of age, it was noted that patients 40-44 y of age were 3.8 times more likely to develop an AMI (OR ¼ 3.76, 95% CI ¼ 1.21, 11.7), 45-to 49-y-old men were also more than three times as likely to have an AMI (OR ¼ 3.14, 95% CI ¼ 1.03, 9.64), and 50-to 55-y-old patients had a four-fold increased risk of developing AMI (OR ¼ 4.04, 95% CI ¼ 1.39, 11.7). The risk becomes more pronounced with increasing age, indicating the need for cardiologists and internists to monitor ED patients who may not necessarily present with cardiovascular symptoms.

show abstract

“…3,4 Moreover, ED is increased in prevalence in hypertensive patients, and it is highly associated with cardiovascular disease. [5][6][7][8][9] The discussion whether in hypertensive patients, high blood pressure itself or the antihypertensive therapy constitutes a cause of ED has always been a controversial point. Antihypertensive drugs are most commonly associated with ED.…”

Section: Introductionmentioning

confidence: 99%

Candesartan cilexetil protects cavernous tissue in spontaneously hypertensive rats

Toblli

Stella²,

Mazza

et al. 2004

Int J Impot Res

View full text Add to dashboard Cite

In previous experiments, our group demonstrated morphological changes in erectile tissue from male spontaneously hypertensive rats (SHR). The present study was performed to determine whether an angiotensin II receptor blocker could protect cavernous tissue (CT) from these structural alterations in SHR. Male SHR and Wistar-Kyoto (WKY) rats were studied during 4 months. Rats were divided into three groups: SHR (n ¼ 10), SHR with candesartan cilexetil (n ¼ 10) and WKY rats (n ¼ 10). Candesartan cilexetil 7.5 mg/kg/day was administered orally throughout the study. CT was processed for pathology studies. The amount of (1) cavernous smooth muscle (CSM), (2) vascular smooth muscle (VSM), (3) collagen type III, and the rat endothelial cell antibody (RECA-1)/tunica media ratio in cavernous arteries were evaluated. SHR with candesartan cilexetil showed a lower blood pressure, a lower percentage of CSM, smaller VSM area, with a higher RECA-1/media ratio, and a lower percentage of collagen type III, when compared to untreated SHR. In addition, SHR showed a positive correlation between systolic blood pressure (SBP) and CSM amount (r ¼ 0.91; Po0.01), and SBP and the percentage of collagen type III (r ¼ 0.88; Po0.01); these correlations were not observed either in SHR treated with candesartan cilexetil or in WKY rats. We conclude that candesartan cilexetil provides a significant protective role against morphologic changes in vessels as well as in cavernous spaces of the erectile tissue, caused by high blood pressure, in SHR.

show abstract

Erectile dysfunction is a marker for cardiovascular complications and psychological functioning in men with hypertension

Cited by 87 publications

References 32 publications

Prevalence of erectile dysfunction and its correlates in Egypt: a community-based study

Prevalence of erectile dysfunction and its correlates in Egypt: a community-based study

Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study

Candesartan cilexetil protects cavernous tissue in spontaneously hypertensive rats

Contact Info

Product

Resources

About